MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

• Status: Terminated
• Trial end date: 2009-05-20
• Target enrollment: 0
• Participant gender: All

Summary

A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Patient is 18 years of age or older

• Patient has had a history of migraine with or without aura

• Patient is able to complete study questionnaire(s) and paper diary

Exclusion Criteria:

• Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of the study

• Patient has basilar or hemiplegic migraine headache, hepatitis or psychiatric conditions

• Patient was older than 50 years of age at migraine onset

• History of gastric or small intestinal surgery or has a disease that causes malabsorption

• Patient has heart attack, unstable angina, coronary artery bypass surgery or other revascularization procedure, stroke, or transient ischemic attack 3 months before starting the study

• Currently participating or has participated in a study with an investigational compound or device within 30 days of starting the study

• Currently participating in a study with MK-0974 or MK-3207